Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients chronically infected with hepatitis C virus (HCV) genotype 1~* HCV RNA viral load of ≥10\*5\* IU/mL (100,000 IU/mL) at screening~* Treatment naive~Key Exclusion Criteria:~* Women of child-bearing potential~* Cirrhosis~* Coinfection with HIV or hepatitis B virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) (Type: EXPERIMENTAL): Active Comparator
- Daclatasvir, Peginterferon alpha-2a, ribavirin (B) (Type: EXPERIMENTAL): Active Comparator
- Daclatasvir, Peginterferon alpha-2a, ribavirin (C) (Type: EXPERIMENTAL): Active Comparator
- Placebo, Peginterferon alpha-2a, ribavirin (D) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).